|
| | Publication Year | Title | Author(s) |
| 381 | 14-Jul-2023 | Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2. | Wichmann, Christian Werner; Burvenich, Ingrid Julienne Georgette; Guo, Nancy; Rigopoulos, Angela; McDonald, Alexander; Cao, Diana; O'Keefe, Graeme Joseph; Gong, Sylvia Jie; Gan, Hui K ; Scott, Fiona Elizabeth; Pore, Nabendu; Coats, Steven; Scott, Andrew Mark |
| 382 | 15-Aug-2008 | Predicting clinical outcome through molecular profiling in stage III melanoma. | John, Thomas ; Black, Michael A; Toro, Tumi T; Leader, Debbie; Gedye, Craig A; Davis, Ian D; Guilford, Parry J; Cebon, Jonathan S |
| 383 | 8-Jul-2021 | Predicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma. | Wight, Joel C ; Wai, Shin Hnin; Shen, Edward; Lee, Sze Ting ; Berlangieri, Salvatore U ; Fancourt, Tineke ; Hawkes, Eliza A ; Hannah, Anthony; Leung, Teresa; Chong, Geoffrey |
| 384 | 1-Oct-2022 | Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX. | van Dijk, Erik; van Werkhoven, Erik; Asher, Rebecca; Mooi, Jennifer K ; Espinoza, David; van Essen, Hendrik F; van Tinteren, Harm; van Grieken, Nicole C T; Punt, Cornelis J A; Tebbutt, Niall C ; Ylstra, Bauke |
| 385 | Jun-2020 | Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. | Brockwell, Natasha K; Alamgeer, Muhammad; Kumar, Beena; Rivalland, Gareth; John, Thomas ; Parker, Belinda S |
| 386 | 13-May-2018 | Pretreatment risk stratification of feeding tube use in patients treated with intensity-modulated radiotherapy for head and neck cancer. | Anderson, Nigel J; Jackson, James E; Smith, Jennifer G; Wada, Morikatsu ; Schneider, Michal; Poulsen, Michael; Rolfo, Maureen; Fahandej, Maziar; Gan, Hui K ; Joon, Daryl Lim; Khoo, Vincent |
| 7 | 20-Nov-2014 | Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. | Chia, Puey Ling ; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
| 8 | May-2021 | Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma. | Lee, Sze Ting ; Muralidharan, Vijayaragavan ; Tebbutt, Niall C ; Wong, P; Fang, C; Liu, Z; Gan, Hui K ; Sachinidis, J; Pathmaraj, Kunthi ; Christophi, Christopher ; Scott, Andrew M |
| 9 | 21-May-2007 | Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. | Lee, S T; Berlangieri, Salvatore U ; Poon, A M T; Mitchell, Paul L R ; Pathmaraj, K ; Tabone, K; Byrne, Amanda J; O'Keefe, Graeme J; Knight, Simon R ; Clarke, C Peter; Scott, Andrew M |
| 10 | 7-Oct-2009 | Primary anaplastic pilocytic astrocytoma. | Azad, Arun A; Deb, Siddhartha; Cher, Lawrence M |
| 11 | May-2022 | Primary CNS lymphoma in the real world-Opportunities for improved outcomes in different health settings | Parakh, Sagun ; Gan, Hui K |
| 12 | 1-Jun-2021 | Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. | Yin, Jun; Cohen, Romain; Jin, Zhaohui; Liu, Heshan; Pederson, Levi; Adams, Richard; Grothey, Axel; Maughan, Timothy S; Venook, Alan; Van Cutsem, Eric; Punt, Cornelis; Koopman, Miriam; Falcone, Alfredo; Tebbutt, Niall C ; Seymour, Matthew T; Bokemeyer, Carsten; Rubio, Eduardo Diaz; Kaplan, Richard; Heinemann, Volker; Chibaudel, Benoist; Yoshino, Takayuki; Zalcberg, John; Andre, Thierry; De Gramont, Aimery; Shi, Qian; Lenz, Heinz-Josef |
| 13 | 1-Nov-2018 | The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. | Mooi, Jennifer K ; Wirapati, P; Asher, R; Lee, C K; Savas, P S; Price, T J; Townsend, A; Hardingham, J; Buchanan, D; Williams, D ; Tejpar, S; Mariadason, John M ; Tebbutt, Niall C |
| 14 | Nov-2023 | The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review. | Allan, Zexi; Witts, Sasha; Tie, Jeanne; Tebbutt, Niall C ; Clemons, Nicholas J; Liu, David Shi Hao |
| 15 | 20-Feb-2021 | Prognostic performance of qSOFA in oncology patients admitted to the emergency department with suspected infection. | Koh, Tze Lui ; Canet, Emmanuel; Amjad, Sobia; Bellomo, Rinaldo ; Taylor, David McD ; Gan, Hui K ; Marhoon, Nada ; Lim, Andrew Boon Ming ; Ong, Wee Loon ; Krishnan, Vivek; Khor, Richard |
| 16 | 15-Feb-2021 | Prognostic Significance of Post-Surgery Circulating Tumor DNA in Non-Metastatic Colorectal Cancer: Individual Patient Pooled Analysis of Three Cohort Studies. | Tie, Jeanne; Cohen, Joshua D; Lo, Serigne N; Wang, Yuxuan; Li, Lu; Christie, Michael; Lee, Margaret; Wong, Rachel; Kosmider, Suzanne; Skinner, Iain; Wong, Hui Li; Lee, Belinda; Burge, Matthew E; Yip, Desmond; Karapetis, Christos S; Price, Timothy J; Tebbutt, Niall C ; Haydon, Andrew M; Ptak, Janine; Schaeffer, Mary J; Silliman, Natalie; Dobbyn, Lisa; Popoli, Maria; Tomasetti, Cristian; Papadopoulos, Nickolas; Kinzler, Kenneth W; Vogelstein, Bert; Gibbs, Peter |
| 17 | 28-Mar-2009 | Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. | Lee, S T; Ghanem, M; Herbertson, R A; Berlangieri, Salvatore U ; Byrne, Amanda J; Tabone, K; Mitchell, Paul L R ; Knight, Simon R ; Feigen, Malcolm; Scott, Andrew M |
| 18 | Jan-2020 | Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. | Brown, Helen; Vansteenkiste, Johan; Nakagawa, Kazuhiko; Cobo, Manuel; John, Thomas ; Barker, Craig; Kohlmann, Alexander; Todd, Alexander; Saggese, Matilde; Chmielecki, Juliann; Markovets, Aleksandra; Scott, Marietta; Ramalingam, Suresh S |
| 19 | 21-Jun-2016 | Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. | Gray, H J; Benigno, B; Berek, J; Chang, J; Mason, J; Mileshkin, L; Mitchell, Paul L R ; Moradi, M; Recio, F O; Michener, C M; Secord, A Alvarez; Tchabo, N E; Chan, J K; Young, J; Kohrt, H; Gargosky, S E; Goh, J C |
| 20 | 26-Sep-2017 | Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. | Chüeh, Anderly C; Liew, Mun-Sem; Russell, Prudence A; Walkiewicz, Marzena; Jayachandran, Aparna; Starmans, Maud H W; Boutros, Paul C; Wright, Gavin; Barnett, Stephen A ; Mariadason, John M ; John, Thomas |
